Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a ...

The generic drug segment, a key driver of Amneal’s business, has shown particularly impressive growth. Analysts project a 17% growth for the generic segment in the third quarter of 2024 ...

In August 2024, the FDA approved Amneal’s IPX203 for Parkinson’s disease as Crexont (Carbidopa and Levodopa) extended-release capsules. The generic drug was launched in September. J.P. Morgan ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ...

(Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience (“mAbxience”) today announced that the U.S. Food and Drug Administration (FDA) has ...

In August 2024, the FDA approved Amneal’s IPX203 for Parkinson’s disease as Crexont (Carbidopa and Levodopa) extended-release capsules. The generic drug was launched in September. J.P. Morgan analyst ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) stands ...